Glenmark launches unique fixed dose combination drug for diabetes

Glenmark launches unique fixed dose combination drug for diabetes The Mumbai based drug firm said it has introduced fixed dose combination (FDC) of its novel, patent protected Sodium Glucose Co-Transporter Inhibitor (SGLT2i) – Remogliflozin Etabonate and another widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor) – Vildagliptin, with Metformin.

from Moneycontrol Business News https://ift.tt/3pDpXc4
Posted by: at
Tags:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Start-up Street: Social justice and the start-up ecosystem

Disparities in start-ups are a global phenomenon and affirmative action is needed to ensure an equal opportunities environment for aspiring...